Patrick Schöffski, MD, MPH, of Catholic University Leuven, discusses findings on the effect of crizotinib on disease control in patients with advanced papillary renal cell carcinoma type 1 with MET mutations or amplification (Abstract 580).
Thomas Powles, MD, of Barts Cancer Institute, discusses phase III study findings on atezolizumab vs chemotherapy in platinum-treated locally advanced or metastatic urothelial carcinoma, with an emphasis on immune biomarkers, tumor mutational burden, and clinical outcomes (Abstract 409).
Fatima Karzai, MD, of the National Institutes of Health, discusses phase II findings on olaparib and durvalumab in metastatic castration-resistant prostate cancer in an unselected population (Abstract 163).
Gregory R. Pond, PhD, of McMaster University, discusses a new six-factor prognostic model for patients with advanced urothelial carcinoma receiving post platinum atezolizumab (Abstract 413).
Laurence Albiges, MD, PhD, of the Gustave Roussy Cancer Centre, discusses study findings on the safety and efficacy of nivolumab in metastatic renal cell carcinoma (Abstract 577).
Paul L. Nguyen, MD, of the Dana-Farber Cancer Institute, summarizes a session he chaired on prostate cancer, which included discussion of daily vs weekly image-guided radiotherapy; a biomarker to predict biochemical failure and metastasis; a comparison of abiraterone or enzalutamide activity; and the impact of 18F-fluciclovine PET/CT on clinical management choices for men with biochemically recurrent disease (Abstracts 4, 5, 164, 165).
